Financials
Financial year 2024
ALEXION PHARMA BELGIUM from Brussel, company number BE0895692555, closed financial year 2024 with a result of € 345,015 after tax. For that financial year ALEXION PHARMA BELGIUM recorded revenue of € 19 million and equity of € 3 million. Compared with financial year 2023, the result moved from € 335,522 to € 345,015. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2025.
€ 3 million
▲ 13% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 345,015
▲ 3% vs 2023
Profit after tax over the fiscal year.
€ 106
▼ 99% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 3 million.
People and assets in 2024
8
▲ 1.9 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 1.7 million
▲ 22% vs 2023
€ 208,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 2.7 million
▼ 67% vs 2023
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 62 days on average.
€ 389,847
▲ 41% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | € 13,316,289 | € 13,951,373 | € 15,334,419 | € 19,040,463 | ▲ 24% |
| Profit after taxes | € 311,002 | € 251,619 | € 335,522 | € 345,015 | ▲ 3% |
| Equity | € 2,055,203 | € 2,306,822 | € 2,642,343 | € 2,987,358 | ▲ 13% |
| Total debts | € 4,194,719 | € 6,255,945 | € 8,736,706 | € 5,748,768 | ▼ 34% |
| Cash | € 2,229,100 | € 1,394,696 | € 15,614 | € 106 | ▼ 99% |
| Retained profit | € 2,036,603 | € 2,288,222 | € 2,623,743 | € 2,968,758 | ▲ 13% |
| Balance sheet total | € 6,249,922 | € 8,562,767 | € 11,379,050 | € 8,736,127 | ▼ 23% |
| Employees (FTE) | 4 | 5.8 | 6.1 | 8 | ▲ 1.9 |
Key figures of ALEXION PHARMA BELGIUM, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to ALEXION PHARMA BELGIUM?
What happened at ALEXION PHARMA BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 345,015 (▲ 3% vs 2023). Source: NBB ↗
- New establishment in Dilbeek. KBO
- Luca Taliercio became a director. NBB
- Celine Khalife became a director. NBB
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 311,002 profit in 2021 to € 345,015 profit in 2024.
Paid € 510,452 in corporate taxes since 2021.
Best year ever: 2024, with € 345,015 profit.
Pays suppliers within 62 days on average.
A new publication or filing at ALEXION PHARMA BELGIUM? We notify you, reason included.
Follow ALEXION PHARMA BELGIUMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ALEXION PHARMA BELGIUM are Luca Taliercio and Celine Khalife. Luca Taliercio is also behind ALEXION SERVICES EUROPE.
Directors
According to the 2024 annual accounts
since 2023
Celine Khalife
Director
since 2019
Establishments
Establishment units
Physical locations of this company
Tweekerkenstraat 29-33
1000 Brussel
Alfons Gossetlaan 40
1702 Dilbeek
Active since 31 May 2023
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0895.692.555
- VAT number
- BE 0895.692.555
- Registered office
- Tweekerkenstraat 29-33, 1000 Brussel
- Names & denominations
- ALEXION PHARMA BELGIUM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 13 February 2008
- Peppol
- Active · Active since 20 Nov 2020
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Vervaardiging van geneesmiddelen
Handelsbemiddeling in de niet-gespecialiseerde groothandel
Vervaardiging van farmaceutische grondstoffen